Chemoprevention of cancer is reviewed from the viewpoints of action mechanisms and methodology of clinical trials in order to introduce promising agents discovered by in vitro and/or in vivo studies to applications in humans. The clinical trial procedure essentially follows the phase study which has been employed for chemotherapeutic drugs. Chemoprevention of bladder cancer, prostate cancer, gastric cancer, hepatocellular carcinoma, breast cancer, head and neck cancer, colorectal cancer and lung cancer is reviewed, mainly focusing on clinical trials. Previous clinical trials have shown the effectiveness of the following: polyprenoic acid (acyclic retinoid) for hepatocellular carcinoma; tamoxifen for breast cancer; retinoic acids for head and neck tumor; and aspirin, a COX-2 inhibitor, for colorectal cancer. Despite the advantageous effects of some of these agents, their toxic effects must also be of concern at the same time. For example, in a chemoprevention trial of lung cancer, b-carotene was unexpectedly found to increase the risk of lung cancer among high-risk groups. It is also noted that large-scale clinical trials demand large research grants, which may not be affordable in Japan. Chemoprevention is still an emerging field of oncology where researchers in both basic and clinical sciences face great challenges.
INTRODUCTION
The term 'chemoprevention' was first introduced by Sporn (1) in 1976, in contrast to 'chemotherapy', when he referred to the prevention of development of cancer both by natural forms of vitamin A and by its synthetic analogues, combined called retinoids. This strategy seems to be promising for reducing cancer incidence both in well-defined high-risk groups of people and also in the general population. Chemoprevention is now defined as the use of specific agents to suppress or reverse carcinogenesis and thereby to prevent the development of cancers (2) .
Primary prevention of cancer is one of the key approaches to the control of cancer. It includes (i) avoiding exposure to known cancer-causing agents, (ii) enhancement of host defense mechanisms, (iii) modifying life style and (iv) chemoprevention. Thus, the National Cancer Institute (NCI) in the USA has given priority to cancer prevention research in such diverse areas as diet and nutrition, tobacco cessation, chemoprevention and early detection and screening (3) . The NCI also sponsors small-and large-scale clinical trials for this purpose. The final goal of all those programs is to achieve reductions in cancer incidence and mortality.
As President of National Cancer Center, Japan, I completely agree with this strategy of the NCI. In addition to the four approaches mentioned above, however, prevention and eradication of tumor-associated viruses, bacteria and parasites should be emphasized. This review stresses the importance of chemoprevention.
I. MECHANISMS OF ACTION OF CHEMOPREVENTIVE AGENTS
Findings obtained so far from carcinogenesis experiments, chemical/biological sciences, pathology and epidemiology have promoted our understanding of the basic mechanisms of chemoprevention. Cancer chemoprevention may target various processes such as those listed in Table 1 , originally proposed by Kelloff et al. (4) .
CARCINOGEN-BLOCKING ACTIVITIES

INHIBITION OF CARCINOGEN UPTAKE
As an example of this mechanism, calcium is listed. It inhibits colon tumor formation and colonic mucosal hyperproliferation in rats. The effect was attributed to a combination of calcium ions and excess bile and free fatty acids in the colonic lumen (5) . This experimental observation also suggests that other chelating agents may have chemopreventive potential by inhibiting carcinogen uptake to the body.
INHIBITION OF CARCINOGEN FORMATION/ACTIVATION
A very good example of this mechanism is inhibition of the formation of carcinogenic nitrosamines by water-soluble vitamin C or oil-soluble vitamin E, which block the reaction between secondary amines and nitrite under very acidic conditions in the stomach (6) .
Carcinogen formation can also be inhibited by preventing metabolic activation of a procarcinogen. Many chemopreventive agents (e.g. allylic sulfides, arylalkyl isothiocyanates, carbamates and flavonoids) exhibit this type of activity. Several compounds that inhibit aromatase also inhibit chemical carcinogenesis in estrogen-sensitive tissues (7) .
DEACTIVATION/DETOXICATION OF CARCINOGENS
Carcinogen deactivation and detoxication constitute a very important mechanism of chemoprevention. Two metabolic pathways are related. One is the phase I metabolic enzymes, which are primarily the microsomal mixed-function oxidases. The polar groups of chemicals (e.g. hydroxyl group) become substrates for this conjugation. The other pathway is by the phase II metabolic enzymes related to conjugation and formation of glucuronides, glutathione (GSH) conjugates and sulfates.
GSH is a prototype carcinogen scavenger. It reacts spontaneously or via catalysis by GSH S-transferases (GSTs) with numerous activated carcinogens such as MNNG, AFB1 and B[a]P diol epoxide and other activated polycyclic aromatic hydrocarbons (8) .
A number of promising chemopreventive agents belong to this category. Prominent compounds among them are the allylic sulfides, which are natural products found in onion, garlic and other Allium genus vegetables. Oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] is a potent GST inducer with a wide spectrum (9) . N-Acetyl-L-cysteine (NAC) is essentially a precursor of GSH (4). 
Action
Candidate agent
Carcinogen-blocking activities
Inhibit carcinogen uptake Calcium
INHIBITION OF ARACHIDONIC ACID (AA) METABOLISM
AA is metabolized by oxidative enzymes to prostaglandins (PGs), thromboxanes, leukotrienes and so forth. Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) are useful chemopreventive agents for colon cancer. Those drugs are potent inhibitors of cyclooxygeneses, enzymes that catalyze the synthesis of prostaglandins from AA. These drugs have attracted much attention from the viewpoint of the relationship between cancer and inflammation (11).
ANTIPROLIFERATION/ANTIPROGRESSION ACTIVITIES
MODULATION OF SIGNAL TRANSDUCTION
It is of interest to regard carcinogenesis as a disorder of signal transduction. Hormones and growth factors that regulate cell growth, proliferation and differentiation communicate across cell membranes, via receptors and receptor-associated enzymes. Second messengers which convey information between the cell membrane and the nucleus through cytoplasm include cyclic adenosine monophosphate, inositol (1,4,5)-trisphosphate, diacylglycerol, prostaglandins and regulatory proteins such as mitogen-activated protein (MAP) kinases. The various steps of signal transduction are potential target sites for chemoprevention in restoring normal cellular controls (12) .
MODULATION OF HORMONAL/GROWTH FACTOR ACTIVITY
The regulation of cell growth and proliferation may occur at multiple levels: hormones and growth factors, membrane/cytoplastic/nuclear receptors (e.g. estrogen, progesterone, retinoid, glucocorticoid, vitamin D and thyroid receptors). Transforming growth factor b (TGF-b) has antiproliferative activity in both normal and neoplastic cells (13) . Insulin-like growth factor 1 (IGF-1) stimulates cell replication in various tumors. These steps are all targets of chemoprevention.
INHIBITION OF POLYAMINE METABOLISM
Polyamines are one of the essential factors in cell proliferation, differentiation and malignant transformation (14) . A critical step in polyamine biosynthesis is the ornithine decarboxylase (ODC)-catalyzed formation of putrescine from ornithine. Chemical agents that inhibit induction of ODC thus possess chemopreventive potential. Difluoromethylornithine (DFMO) is a specific and irreversible inhibitor of ODC.
RESTORATION OF IMMUNE RESPONSE
There are many reports regarding the importance and usefulness of antibodies to oncogene products or oncoproteins (15) . Prostaglandin E 2 is known to suppress the immune response in certain tumor cells and inhibitors of cyclooxygenase diminish this immune suppression. Chemopreventive retinoids work as immuno-stimulants. In fact, retinoic acid enhances cell-mediated and natural killer cell cytotoxicity. Immunostimulative effects of selenium and a-tocopherol have been reported, which may explain part of their action as chemopreventive agents.
II. PROCESSES OF CLINICAL TRIALS TO PROVE THE EFFICACY OF CHEMOPREVENTIVE AGENTS
The development process for establishing a certain specific chemopreventive agent against a particular cancer is basically similar to the process of evaluating an investigative new drug (IND) being approved by the US Food and Drug Administration (FDA). It starts from preclinical evaluation and then continues stepwise to clinical trials. Such mechanisms and systems are most developed in the USA, led by the NCI. The NCI has established a system for a scientific approach to developing chemopreventive agents. Based on epidemiological and basic laboratory research, stepwise clinical trials are conducted and the approval of the FDA is finally obtained for marketing and applying chemoprevention to humans (16).
PRECLINICAL EVALUATION
The animal models most frequently used for initial in vivo screening are azoxymethane-induced rat colon cancer or aber- To choose appropriate chemopreventive agents, sufficient information regarding organotropism is essential. On some occasions, effects of promoting adverse tumors must be considered in organs other than the target. For example, although naturally occurring and synthetic antioxidants inhibit liver carcinogenesis, they promote tumor development or may even induce cancer in other organs at the same time (17) . Thus, appropriate experimental protocols are necessary to assess wide-spectrum organ systems to clarify whether any particular agent might have practical application as a chemopreventive compound. Ito and Imaida (18) developed models of multiorgan carcinogenesis systems using male and female B6C3F1 mice treated with N,N¢-dimethylnitrosamine (DEN) and Nmethyl-N¢-nitrosourea (MNU) or using F344 male and female rats treated with DEN, MNU, N-butyl-N-4-hydroxybutylnitrosamine (BHBN), 1,2-dimethylhydrazine (DMH) and N,N-bis(2-hydroxy)propylnitrosamine.
If the results from those in vivo assays are promising, then the compounds are further processed for in-depth efficacy evaluation and preclinical toxicity and pharmacokinetic testing. In the USA, the FDA requires the data from preclinical toxicology studies to qualify agents to be used safely in clinical trials in human subjects. Those studies include acute and subchronic toxicity and pharmacokinetics. If the developmental process proceeds further, it is required to investigate the effects of the agent on the reproductive system, their potential for carcinogenesis and drug-specific effects such as neurotoxicity and other adverse effects. Only agents proved to have high efficiency and low toxicity at this stage in animal models are allowed to proceed further for clinical evaluation.
In the USA, these processes are supervised by the NCI; however, in Japan there is no national agency having such a capacity and authority. Pharmaceutical companies are not interested in developing chemopreventive agents mainly for economic reasons. For appropriate expansion of research in this field in Japan, the Ministry of Health, Labor and Welfare should make great efforts to establish guidelines for researchers.
EARLY-PHASE CLINICAL TRIALS
If agents show promising results in the preclinical studies, they are evaluated in an early-phase clinical trial to determine the dose-related safety and pharmacokinetics. For those chemopreventive agents which are already used in humans and the pharmacokinetics of which are well known (such as b-carotene and vitamin A), this phase I trial is omitted. Also, further phase I studies may be allowed to be skipped for drugs already approved for use for other purposes in humans at doses and durations greater than or equal to those planned for chemopreventive trials.
PHASE II TRIALS
Phase II chemopreventive trials are randomized, blinded, placebo-controlled studies, requiring 50-100 subjects or patients for each arm for the chemopreventive agent being administered for 6 months to 1 year. A primary objective of these short-term phase II trials is the identification and validation of intermediate surrogate biomarkers accurately predicting the future occurrence of cancer in a relatively short period.
At the NCI, cancers of 10 different organs are currently being targeted for chemopreventive phase II trials, namely the colon, prostate, lung, breast, bladder, cervix, oral cavity, esophagus, liver and skin. The high incidences and mortality rates of these cancers are well known (19) . Two examples of such trials are (i) tamoxifen and N-(4-hydroxyphenyl)retinamide (4-HPR) for patients scheduled for breast biopsy, assessing the histopathological effects of these two agents, either singly or in combination, and (ii) trials in China using oltipraz against aflatoxin B 1 , (AFB1)-induced liver cancers, evaluating the modulation of carcinogen-DNA adducts in serum and urine (2) . If we can use an intermediate biomarker such as cholesterol levels to detect the progression of atherosclerosis as a surrogate marker for myocardial infarction risk (20) , it would be very helpful to conduct chemopreventive trials. Some examples of the intermediate biomarkers used in chemopreventive trials are dysplasia and/or intraepithelial neoplasia, which are used in cervical and prostate cancer. Other chemopreventive trials are in progress using as biomarkers dysplastic oral leukoplakia, Barret's oesophagus, colorectal polyps, superficial papillary bladder cancers, bronchial dysplastic metaplasia and atrophic gastritis.
PHASE III TRIALS
If a promising agent meeting the criteria of high efficacy and low toxicity is identified, phase III chemopreventive trials may be conducted. Such trials take a long time, at least 5-10 years or longer, to complete, because, since cancer incidence is usually taken as the primary endpoint, considerable resources are needed. The NCI uses review criteria to assess the merits of a proposed large-scale trial in relation to the extent to which the trial proposed may reduce the cancer incidence and mortality. On-going trials and completed trials will be discussed later in the section for each organ system. A wide range of findings must be taken into account before a particular agent is recognized as preventing cancers, summarized in Table 2 according to IARC.
III. CHEMOPREVENTION OF VARIOUS CANCERS
This section briefly reviews the chemoprevention of cancers in various organs such as the bladder, prostate, stomach, colorectum, liver, breast and head and neck, concentrating mainly on human trials. For bladder cancer, as a starting point of the review, both animal experiments and clinical trials will be discussed. (21, 22) . This review concentrates on the oral agents that have been shown to exhibit effects in decreasing the incidence or recurrence of bladder cancers both in animals and in humans. Intravesicular instillation of chemotherapeutic and immunogeneic agents is the mainstay of prophylaxis against bladder cancer but will not be touched upon in this review.
The mechanism behind the high rate of intravesical recurrences has long been debated between two theories: implantation of cancer cells versus multifocal carcinogenesis in field cancerization (23) . Multiple random biopsies during TUR for bladder cancer or step-section analysis of cystectomized specimens often show a multifocal distribution of carcinoma in situ (CIS)/dysplasia in the normal-appearing bladder mucosa (24) . These findings support multifocal tumor development in different stages of disease. In fact, similar neoplastic and/or preneoplastic lesions such as CIS and/or dysplasia are detected in the renal pelvis and ureter in association with renal pelvic and ureteral cancers. On the other hand, recent molecular analyses of multifocal bladder cancers or metachronous bladder cancer after nephroureterectomy for renal pelvic and/or ureteral cancer indicate that multifocal cancers in the bladder are of monoclonal origin. This suggests the possibility of implantation of original cancer cells in the bladder (25) (26) (27) (28) . Several reports have used different molecular analysis techniques such as Xchromosome inactivation (25) , analysis of mutation pattern of p53 (27) , loss of heterozygosity (LOH) and microsatellite shifts (28) to elucidate how multiple bladder cancers arise from the dispersion of a single transformed cell.
By analyzing the hazard curve of recurrences after TUR, Akaza et al. (29) demonstrated a biphasic recurrence curve with an initial peak within 3-6 months and the second peak between 1.5 and 2.5 years (Fig. 1) . The natural course of bladder carcinogenesis after TUR is probably a mixture of implantation and field carcinogenesis. In this respect, the Akaza model coincides with the observations on clonal cells spread in the bladder and the co-existence of CIS/dysplasia in the normal-appearing mucosa.
Intravesical recurrence after TUR is a good target for chemoprevention from various standpoints such as de-differentiation, anti-inflammation, anti-proliferation and anti-angiogenesis. As shown by Kelloff et al. (30) , various steps of the carcinogenesis process can be targeted for chemoprevention. Laboratory and clinical studies on chemoprevention of bladder carcinogenesis will therefore be reviewed. Carcinogenesis is postulated to be a multi-step process including at least initiation and promotion. Cancer chemoprevention aims to stop the carcinogenic process or to prolong the onset of carcinogenesis by intervening with efficacious, non-toxic and inexpensive agents to prevent, suppress or reverse the malignant transformation.
INHIBITION OF FORMATION OF MUTAGENS/CARCINOGENS
Phase II metabolic enzyme inducers such as N-acetyl-Lcysteine, S-allyl-L-cysteine, oltipraz, phanhexyl isothiocyanate are possible candidates (30) . Polyphenols such as ellagic acid and other substances such as curcumin are candidate agents as antimutagens/carcinogen blocking agents (30) . However, most of these agents have not been examined in the bladder carcinogenesis model. From the standpoint of in vivo nitrosation (endogenous formation of volatile nitrosamines in the human at Pennsylvania State University on http://jjco.oxfordjournals.org/ Downloaded from body), vitamins C and E are interesting as candidate agents to inhibit nitrosation in the stomach (6) . Vitamins C and E have antioxidant effects and the suppressive effect of high doses of vitamin C was associated with a 40% reduction of recurrences (31) . Fig. 2 shows the relationship between vitamin A (retinol), retinal and retinoic acid. Vitamin A is a fat-soluble micronutrient and occurs in nature in various forms. Vitamin A (retinol) and dehydroretinol (retinal) can be derived from carotenoids. Vitamin A is retinol which is orally taken as a food. Retinol is converted to retinal by metabolic oxidation and is biologically essential for light perception in the retina. Retinal is further transformed into retinoic acid by strictly controlled metabolic oxidation. The important biological function of vitamin A is mainly through retinoic acid, which has a close relationship with important cellular functions such as morphogenesis, cellular proliferation and cellular differentiation. Fig. 3 shows the major retinoic acids now being used for chemoprevention including bladder cancer. All-trans-aromatic retinoid causes acute promyelocytic leukemia blasts to differentiate into polymorphonuclear leukocytes (32) .
VITAMIN A AND RELATED COMPOUNDS
A retrospective epidemiological study on 569 bladder cancer patients and 1025 age-matched controls indicated an increased risk of bladder cancer associated with lower levels of vitamin A intake, infrequent milk and carrot intake and infrequent consumption of cruciferous vegetables (33) .
Another cohort study (34) showed that serum carotene and retinol levels were significantly lower in patients with bladder cancer than in controls. The effect of 13-cis-retinoic acid was studied by the National Bladder Cancer Collaborative Group A in patients with rapidly recurring bladder cancer. However, because of toxicity, this study was stopped early without showing any benefits. Etretinate has been shown to have a significant inhibiting effect on the recurrence of superficial papillary bladder cancers. Studer et al. (35) organized a prospective randomized double-blind multicenter trial to test the effect of etretinate or placebo on Ta and T1 papillary bladder cancers. The time to first recurrence was similar in both groups. However, the mean interval to subsequent recurrence was significantly longer in the etretinate group and the frequency of TUR per patient-year was significantly reduced. Although toxicity such as cheilitis and dryness of the mucosa and skin was tolerable, the long-term safety of etretinate has not been demonstrated. With regard to the effect of retinoids to prevent cancer, there are also numerous negative studies that make the relationship between bladder cancer and vitamin A confusing.
In animal studies, hypervitaminosis A inhibits squamous metaplasia and squamous carcinoma, while avitaminosis A promotes bladder carcinogenesis by FANFT in mice (36) . Sporn and co-workers (37, 38) reported inhibition by 13-cisretinoic acid of bladder cancer induced by MNU or BHBN. Murasaki et al. (39) reported significant inhibition by all-transaromatic retinoids of BHBN-induced bladder cancer in rats. However, all-trans-aromatic retinoids, when used in humans, showed strong toxicities. Pruritus, conjunctivitis, arthralgia and cheilosis were frequently observed (unpublished data).
According to mice experiments (40), all-trans-4-hydroxyphenylretinamide (4HPR) appears to be the most active and least toxic of the retinoids and may be one of the candidate compounds for future chemopreventive studies. In fact, 4HPR has been reported to be effective in inhibiting prostate carcinogenesis in rats (41) .
VITAMIN B 6 (PYRIDOXINE)
Brown et al. (42) reported that large amounts of tryptophan metabolites such as kynurenine, 3-hydroxykynurenine and 3-hydroxyanthranilic acid were excreted in the urine of bladder cancer patients. When these compounds were instilled into the bladder of mice, they produced bladder cancer. Pyridoxine has the capacity to correct this metabolic variation of tryptophan, which was observed in ~50% of bladder cancer patients. Byar and Blackard (43) studied 118 superficial bladder cancer patients randomized to receive a placebo, 25 mg pyrodoxine p.o. or intravesical instillation of thiotepa. Recurrence rates were 60% in placebo group, 46% in pyridoxine group and 47% in thiotepa group, indicating that pyridoxine was significantly better than placebo and as effective as thiotepa. EORTC (44) also organized a double-blind randomized phase III trial to test the effect of pyridoxine on the recurrence of superficial bladder cancers. This trial accrued 291 patients and demonstrated no significant difference between 20 mg pyridoxine and placebo groups in terms of the time to first recurrence and of the recurrence rate. Discrepancies between the two studies may be explained by the mild chemopreventive effect of pyridoxine, which requires a large number of patients for long observation periods to confirm statistical significance. 
VITAMIN C (ASCORBIC ACID)
Vitamin C is the major water-soluble antioxidant and acts as a free radical scavenger. Vitamin C inhibits malignant transformation in vitro, decreases chromosome damage in lymphocytes caused by exposures to bleomycin and inhibits in vivo nitrosation in the stomach, resulting in decreased levels of serum nitrosamines.
There is epidemiological evidence associating increased intake of fresh fruits and vegetables, i.e. vitamin C along with many other vitamins and micronutrients, with a reduced incidence of various cancers. For stomach cancer, this association may be explained by the inhibition of nitrosation in vivo by vitamin C (6). A similar explanation can be offered for the reduction in vivo of the formation of carcinogenic N-nitroso compounds, including 3-hydroxyanthranilic acid and nitrosamines, by vitamin C, which may be relevant to bladder carcinogenesis (45) .
VITAMIN E (a-TOCOPHEROL)
Vitamin E is a lipid-soluble vitamin among which a-tocopherol is the most potent and abundant and acts as an antioxidant to protect unsaturated lipids in cell membranes and as a free radical scavenger. Vitamin E has a capacity to inhibit N-nitrosation. N-Nitroso compounds have relevance to various cancers. N-Nitrosamines occur in tobacco smoke and nitrite in cured meat. Because of these effects, vitamin E is one of the possible agents for chemoprevention of bladder cancer. Lamm et al. (31) studied the effect of a megadose vitamin combination in a double-blind randomized fashion.
Sixty-five patients with bladder cancer were randomized to receive the recommended daily allowance of multiple vitamins plus 40 000 IU vitamin A, 100 mg vitamin B 6 , 2000 mg, vitamin C and 400 IU vitamin E. The 5-year estimates of bladder cancer recurrence were 91% in the recommended daily allowance group and 41% in the megavitamin group (P = 0.0014) and the overall recurrence was 80 and 40%, respectively (P = 0.0011). Immunopotentiation may also be related to megavitamins, because a statistically significant, long-term increase in natural killer cell activity was observed compared with baseline. In bladder cancer, a significant protective effect is conferred by a combination of high doses of vitamins A, B 6 , C and E (31).
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
NSAIDS such as piroxicam, indomethacin, sulindac and acetylsalicylic acid strongly inhibited bladder carcinogenesis in rats and mice induced by BHBN (46) (47) (48) . A prominent biological activity of NSAIDS is inhibition of prostaglandin synthesis, in particular, inhibition of cyclooxygenase (COX) 1 and 2. However, in humans NSAIDS are associated with toxicities such as gastroduodenal ulcers, bleeding and sometimes gastric perforation due to deep ulceration. These toxicities hampered the long-term use of NSAIDS for chemoprevention. In prostaglandin synthesis, COX-1 and COX-2, the two COX isozymes, are involved. COX-1 is constitutively expressed and contributes to physiological functions in many tissues, whereas COX-2 is inducible and involved in inflammation and cell proliferation. Selective COX-2 inhibitors may become more effective and safer chemopreventive agents than classical NSAIDS, which preferentially inhibit COX-1. One of the COX-2 inhibitors, nimesulide, was reported to be a potent inhibitor of BHBN-induced bladder carcinogenesis in rats (49) . We also confirmed that ~40% of bladder cancer tissues in humans demonstrated positive histochemical staining of COX-2 (unpublished data). Selective COX-2 inhibitors may be a new type of chemopreventor of bladder cancer.
SELENIUM
A micronutrient, selenium may have a chemoprevention effect on bladder cancer. Herzlsouer et al. (50) collected serum samples from 25 802 individuals in Washington County, MD, in 1974. In the subsequent 12-year period, 35 cases of bladder cancer were identified. This cohort study revealed that the level of selenium was significantly lower among cases than two matched controls and there was a nearly linear increase in risk of bladder cancer with decreasing serum selenium level.
DIFLUOROMETHYLORNITHINE (DFMO)
DFMO is an irreversible inhibitor of ornithine decarboxylase and is involved in the synthesis of polyamines and consequently related to cell proliferation. DFMO has been demonstrated to inhibit BHBN-induced bladder carcinogenesis in rats. We tested the dose dependence of DFMO and found that 0.2 and 0.1% DFMO significantly inhibited BHBN-induced bladder carcinogenesis in rats whereas concentrations of 0.03 and 0.01% were ineffective (51). Loprinzi et al. (52) evaluated the toxicity of DFMO in 76 patients randomized to receive 0.125, 0.25, 0.5 or 1.0 g of DFMO daily and demonstrated good tolerance for up to 1 year. Combination treatment with DFMO or 4HPR or both agents, in addition to piroxicam (an NSAID), did not improve chemopreventive potential in rats.
OTHER POSSIBLE CHEMOPREVENTIVE AGENTS
Bropirimine (53), an interferon inducer taken orally, was reported to cause regression in carcinoma in situ lesions of bladder cancer patients. Lactobacillus casei (54) inhibited 26% of recurrences when taken orally after TUR. Oltipraz, which was developed as an antischistosomal agent, has been reported to inhibit chemical carcinogenesis in various organs including the bladder.
So far, chemoprevention of bladder cancer both in humans and animals has been reviewed. Hereafter, for each organ system, only chemoprevention trials conducted in humans will mainly be reviewed, although there are a large number of experiments using animals as reviewed here for bladder cancer.
PROSTATE CANCER
Pathological processes in the prostate during carcinogenesis involve the expansion of multiple clones of proliferating ductal/acinal epithelia being recognized as dysplasia. Well recognized precursor lesions in the peripheral zones are a kind of surrogate for prostate cancer, including high-grade prostatic intraepithelial neoplasia (HGPIN) that appear to develop years before the onset of clinical prostate cancer.
Low-grade prostatic intraepithelial neoplasia (LGPIN) and HGPIN are closely associated with these foci of invasive cancers in the peripheral zones of the prostate. Atypical adenomatous hyperplasia may precede LGPIN and HGPIN. Atypical small acinal proliferation and proliferative inflammatory atrophy in the peripheral zones are often associated with HGPIN. Probably in the ductal/acinal cells, atypical adenomatous hyperplasia, LGPIN, HGPIN and invasive carcinoma are Table 3 . Promising pharmaceutical and natural product classes and their targets for prostate cancer chemoprevention [Lieberman (56) ] 5AR = 5-a-reductase, AR = androgen receptor, ROS = reactive oxygen species, GSTs = glutathione-S transferase, NFkB = nuclear factor-kB, HETE = hydroxyeicosatetraenoic acid, PGE-2 = prostaglandin E2, COX = cyclooxygenase, ASA = acetylsalicylic acid, ER = estrogen receptor, RTK = receptor tyrosine kinase, PS SPES = prostate cancer botanical containing 8 different herbal species, VDR = vitamin D receptor, RXR = retinoic acid ´ receptor, HDAC = histone deacetylase, Rb = retinoblastoma, PSA = prostate specific antigen, PSMA = prostate specific membrane antigen, ODC = ornithine decarboxylase, RAR = retinoic acid receptor, EGFR = epidermal growth factor receptor, VEGFR = vascular endothelial growth factor receptor, PDGFR = platelet-derived growth factor receptor, PPAR = peroxisome proliferator-activated receptor, DHEA = dehydroepiandrosterone, NSAIDs = non-steroidal anti-inflammatory drugs, 15d-PGJ2 = 15-deoxyprostaglandin J2, IGF-1 = insulin-like growth factor, IGFBP-3 = insulin-like growth factor receptor building protein-3, 4APR = N-(4-hydroxyphenyl)retinamide, ET-1 = endothelin-1, IL-6 = interleukin-6, NGF = nerve growth factor, SERMs = selective estrogen receptor modulators. Chemoprevention of prostate cancer can be defined as the administration of natural or synthetic agents that inhibit the multiple steps mentioned above in the natural history of carcinogenesis occurring in the prostate. The goal of prostate cancer chemoprevention is to find effective, non-toxic agents being taken orally that modulate the promotion and progression from normal epithelium to dysplasia to LGPIN and HGPIN to locally invasive carcinoma and metastatic disease. This idea is supported by the significant epidemiological difference concerning the higher incidence of clinical prostate cancer observed in the Western countries than in Asian countries, although the incidences of occult prostate cancer are very similar between Western countries and Japan (55) . The pathological processes of prostate cancer development include a biological spectrum of progressive genetic changes such as loss of heterozygosity on 8p21 involving NKX3.1 and chromosome 10, oxidized DNA bases, epigenetic phenomena such as inactivation of GST-P1 expression and loss of p27 expression and biochemical changes such as elevated PSA and IGF-1 occurring a long time before prostate cancer develops. Some of the promising pharmaceutical and natural product classes and their targets summarized by Lieberman (56) are shown in Tables 3 and 4 . Agents currently in phase II developmental, translational and efficacy trials sponsored by the NCI include DFMO, DFMO and/or Casodex, toremifene, vitamin D analog (Hectoral), selective COX-2 inhibitors (Celecoxib), sulindac sulfone (Exisulinol), genistein-enriched soy isoflavones, soy protein, nutritional products (lycopene, soy isoflavones) and selenized yeast.
In the early 1990s, NCI initiated the first large-scale phase III trial called the Prostate Cancer Prevention Trial (PCPT) (57), using the 5a-reductase inhibitor finasteride in over 18 000 healthy men. Definitive results of this trial are expected in 2003. Since PCPT clearly demonstrated the feasibility of largescale trials for prostate cancer prevention, NCI initiated the second major phase III prostate cancer prevention trial called SELECT (58) , which will test the preventive effects of a-tocopherol and selenium in over 32 000 healthy men at average risk, asymptomatic men 50 years or older with normal PSA for prostate cancer. Furthermore, selenium and flutamide are being evaluated in prevention trials sponsored by the NCI in high-risk subjects with HGPIN (selenium, flutamide) or elevated PSA (selenized yeast) (59, 60) .
In 1998, the effect of supplemental dietary selenium on the incidence of prostate cancer was tested (61) . A total of 974 men with a history of either basal cell or squamous cell carcinoma of the skin were randomized to either a daily supplement of 200 mg of selenium or a placebo. Patients were treated for a mean of 4.5 years and followed for a mean of 6.5 years. Selenium treatment was associated with a significant (63%) reduction in the secondary endpoint of prostate cancer incidence during 1983-93. There were 13 prostate cancer cases in the selenium-treated group and 35 cases in the placebo group (RR = 0.37, P = 0.002). Selenium showed no protective effects against the primary endpoint of squamous and basal cell carcinomas of the skin.
In addition, as summarized by Lieberman (56) in Table 4 , many NCI-supported clinical trials in high-risk populations for prostate cancer (subjects with HGPIN, subjects with elevated PSA and negative biopsies and subjects scheduled for radical prostatectomy) are now in progress, testing many natural and synthetic agents such as antiandrogens, antiestrogens, vitamin D analogs, COX-2 inhibitors and a variety of antioxidants (selenium, lycopene, soy isoflavones).
Principles of combination of various agents are (i) using two or more agents with different mechanisms of action, (ii) using agents with non-overlapping toxicity and (iii) reducing the dose of each agent.
Considering the long latency period of prostate carcinogenesis, cohorts for chemoprevention include asymptomatic males over the age of 55 years (white males) or age 50 years (African Americans) with normal total PSA, men with borderline elevations of PSA, men with consistent elevations of PSA and a negative biopsy, men with a strong family history of early onset of prostate cancer, men with suspicious histological changes including atypia and proliferative imflammatory atrophy, men with HGPIN, patients with low volume/low Gleason grade localized cancer allocated for watchful waiting, patients at high risk for recurrence following surgery or radiotherapy and so forth.
Considering the higher incidences of prostate cancer in Western countries and its sharply increasing trend in some Asian countries including Japan, a new era of prostate cancer chemoprevention has begun, although we still have very few definite results of clinical trials.
One issue that we have to consider seriously is the economic aspects of clinical trials. To run a phase III trial in EORTC, the average cost per patient involved is between US$1000 and 2000. One may calculate that for a sample-size of 30 000 men, US$20-40 million are needed, not including hospital visits, examinations and biopsies. Economic considerations will be the largest obstacle in the future (62).
GASTRIC CANCER
Epidemiological and experimental studies have elucidated the risk factors for gastric cancer such as high salt intake, Helicobacter pylori infection, endogenous nitrosamine formation and, less so, infrequent taking of vegetables and fruits.
Since the discovery of Helicobacter pylori in 1983 (63), the management of upper gastrointestinal disease has changed drastically. In the 1990s, various epidemiological and laboratory studies revealed that Helicobacter pylori, a Gram-negative bacterium commonly detected in the stomach, increased the risk of gastric cancer in human beings.
Evidence suggesting a link between Helicobacter pylori infection and risk of gastric cancer has primarily come from epidemiological and clinical studies. In a study in the UK (64), 29 cases of gastric cancer were identified from two cohort studies, one of 20 179 men and one of 2512 men. Using nested case-control analysis, the prevalence of Helicobacter pylori infection was compared between cases and controls selected among the cohorts. Patients with Helicobacter pylori infection had a risk of gastric cancer 2.8 times higher than those without infection. Parsonnet et al. (65) reported an odds ratio of 3.6 from a nested case-control analysis of 109 patients with gastric cancer identified from a cohort of 188 992 residents of California. Nomura et al. (66) reported an odds ratio of 6.0 from a nested case-control analysis of 7498 Japanese men living in Hawaii. Uemura et al. (67) prospectively studied 1526 Japanese patients who had duodenal ulcers, gastric ulcers, gastric hyperplasia or nodular dyspepsia at the time of enrollment. Of these, 1246 had Helicobacter pylori infection and 280 did not. Patients underwent endoscopy with biopsy at the time of enrollment and then between 1 and 3 years afterwards. The mean follow-up was 7.8 years. Gastric cancers were detected in 36 (2.9%) of the infected and none of the uninfected patients. Those with histological findings of severe gastric atrophy, corpus-predominant gastritis or intestinal metaplasia are at increased risk.
Helicobacter pylori infection is very common, but only a small proportion of people infected with the bacterium develop gastric cancer. Such infection is therefore not sufficient, in itself, to cause gastric cancer. One possible explanation is that the infection induces predisposing pathological changes in the gastric mucosa, such as atrophic gastritis and intestinal metaplasia, which in turn increase the risk of gastric cancer.
Saitoh et al. (personal communication) organized a prospective randomized trial covering all Japan to study the chemopreventive effect of Helicobacter pylori eradication by administering a combination of antibiotics and proton-pump inhibitor for 1 week. However, since many patients wanted to be eradicated of the bacteria when they knew that they were infected with Helicobacter pylori, they were forced to change the trial design from observing the decreased incidence of gastric cancer in the Helicobacter pylori eradicated group to observing the effect of eradication on status of atrophic gastritis or intestinal metaplasia. This trial is still in progress and will be opened in 2004.
There is strong epidemiological evidence that diets high in fruits and vegetables are associated with a reduced risk in several cancers, including cancers of the esophagus and stomach. The people of Linxian County, China, have one of the world's highest rates of esophageal/gastric cardia cancer and a persistently low intake of several micronutrients. Individuals living in four Linxian communes of ages 40-69 years were recruited in 1985 (68). Mortality and cancer incidence during March 1986 and May 1991 were ascertained for 29 584 people who received daily vitamin and mineral supplementation throughout this period. The subjects were randomly assigned to intervention groups according to a 2 4 factorial experimental design: (A) retinol and zinc, (B) riboflavin and niacin, (C) vitamin C and molybdenum and (D) b-carotene, vitamin E and selenium. Doses ranged from one to two times the US Recommended Daily Allowances. A total of 2127deaths were observed during the intervention period. Cancer was the leading cause of death, with 32% of all deaths being due to esophageal or stomach cancer. Significant lower total mortality occurred among those receiving supplementation with b-carotene, vitamin E and selenium (RR = 0.91, P < 0.03). The reduction was mainly due to lower cancer rates (RR = 0.87), especially gastric cancer. This was an NIH-sponsored large-scale, population-based chemopreventive study. However, as already stated, people living in Linxian County are known to take persistently low levels of several micronutrients. Therefore, the situation in Western countries and Japan may be different and it may not be possible to apply this result to people living in these developed countries.
(-)-Epigallocatechin gallate (EGCG) is the main constituent of green tea polyphenols. EGCG and green tea extract in drinking water inhibited carcinogenesis of various organs including the stomach (69) . In 1986, 8552 individuals aged over 40 years in Saitama Prefecture were surveyed on their living habits, including daily consumption of green tea. During the 10 years since 1986, 419 cancer patients were found among participants in the cohort study. Their daily green tea consumption was divided into three groups: <3 cups (120 ml/cup), 4-9 cups and >10 cups per day. Nakachi et al. (70) calculated the average age at cancer onset of all these patients from clinical charts. Cancer onset for patients who had consumed >10 cups of green tea per day was 7.3 years later among females and 3.2 years later among males compared with patients who had consumed <3 cups per day. Hong initiated the first clinical trials of green tea extract with humans in the USA, in a population that had not previously been consuming green tea. In 1997, the US FDA approved a phase I clinical trial with green tea capsules. Since then, various trials have been in progress in the USA, and we have to wait for the results of clinical trials of green tea extract or EGCG or green tea itself.
We started a randomized controlled trial in order to assess the effects of diet supplementation with b-carotene and vitamin C on the development of gastric cancer for high-risk persons with chronic atrophic gastritis in a district of Akita Prefecture in north-eastern Japan, one of the regions with the highest mortality from gastric cancer in Japan. However, in response to an NCI press report (71) released on January 18, 1996, indicating that two b-carotene trials conducted in Finland and the USA exhibited no benefit and potential harm owing to increasing the risk of lung cancer from the supplement, we modified the study protocol and halted the supplementation of b-carotene (72) .
In 2003, we obtained the results of the above-mentioned trial to examine the effect of vitamin C supplementation on serum pepsinogen (PG) level, Helicobacter pylori infection and cytotoxin-associated gene A (Cag A) status. Among 635 subjects diagnosed as having chronic gastritis on the bases of serum PG levels, after excluding ineligible cases, 439 subjects were assigned to one of four groups using a 2 ´ 2 factorial design (0 or 15 mg/day b-carotene and 50 or 500 mg/day vitamin C). Although b-carotene was discontinued as indicated above, vitamin C supplementation was continued. Finally, 120 subjects in the low-dose group of vitamin C 50 mg/day and 124 subjects in the high-dose group of vitamin C 500 mg/day at Pennsylvania State University on http://jjco.oxfordjournals.org/ Downloaded from completed the 5-year supplementation. The difference in the change of PG I/II ratio between baseline and after a 5-year follow-up was statistically significant between the intervention groups among those who completed the supplementation: -0.25 for the low-dose group and -0.13 for the high-dose group (P = 0.0046). We concluded that vitamin C supplementation may protect against progression of gastric mucosal atrophy (73).
HEPATOCELLULAR CARCINOMA
Hepatocellular carcinomas (HCC) are common in Asian countries where hepatitis B virus (HBV) and hepatitis C virus (HCV) infection prevail. One of the well-known biological characteristics of HCC is the high rate of recurrences in the remaining liver after complete resection of the primary tumor. Three years after resection, the incidence of recurrences of HCC in the remnant liver is as high as 70% (74) . It is a good target of chemoprevention to control this high rate of tumor recurrences for high-risk patients.
The relationship between HCV and HBV infection and sequential series of events in hepatocellular carcinogenesis is illustrated schematically in Fig. 4 .
INTERFERON-a (IFN-a)
Hoofnagle et al. (75) reported the efficacy of IFN-a in non-A, non-B chronic active hepatitis. Since then, several randomized trials have shown that IFN-a therapy leads to a rapid decrease in serum alanine aminotransferase (ALT) activity and to a disappearance of serum HCV RNA in about one-third of patients with chronic hepatitis C (76).
Nishiguchi et al. (77) evaluated the effects of IFN-a in cirrhotic patients with HCV infection because of their high risk of HCC in a prospective randomized controlled trial. Ninety patients with compensated chronic active hepatitis C with cirrhosis were randomly allocated to receive IFN-a, 6 MU, 3´/week for 12-24 weeks, or symptomatic treatment and then were followed up for 2-7 years. In some patients, ALT decreased in both the treatment group and control. However, the mean change in ALT was not significantly different between the two groups. Hepatitis C viral RNA disappeared in seven (16%) of the 45 IFN-a-treated patients and in none of the 45 controls. HCC was detected in two (4%) IFN-a patients and 17 (38%) controls, as illustrated in Fig. 5 .
These data clearly show that IFN-a improved liver function in chronic active hepatitis C with cirrhosis and its use was associated with a decreased incidence of HCC.
The mechanism by which IFN-a reduces the incidence of HCC is not known. One possibility suggested is activation of the host immune system.
ADOPTIVE IMMUNOTHERAPY
Between 1992 and 1995, Takayama et al. (78) conducted a randomized trial on 150 patients who had undergone curative Time to first recurrence in the immunotherapy group was significantly longer than that in the control group (48 vs 33% at 3 years, 38 vs 22% at 5 years, P = 0.008) (Fig. 6 ).
The immunotherapy group had significantly longer recurrence-free survival (P = 0.01) and disease-specific survival (P = 0.04) than the control group. Overall survival did not differ significantly between the groups (P = 0.09). Thus, adoptive immunotherapy is a safe, feasible treatment that can lower recurrence and improve recurrence-free outcomes after surgery for HCC. However, it may be difficult to define this treatment as chemoprevention of HCC, because the administration is via the venous route and the cost of lymphocyte treatment is high.
ACYCLIC RETINOIDS
In 1981, Muto et al. (79) reported that 20-carbon polyprenoic acid (Fig. 7) binds to cellular retinoic acid-binding protein and has relatively low toxicity. This agent, called acyclic retinoid, inhibits chemically induced HCC in rats (80) and spontaneous HCC in mice and suppresses cell growth and the production of a-fetoprotein in human HCC-derived cells (81) . The same authors, after a phase I study using acyclic retinoid, conducted a prospective randomized trial (82) on 89 patients who were free of disease after complete resection of HCC or the percutaneous injection of ethanol. They randomly assigned the patients to receive either polyprenoic acid 600 mg/day or placebo for 12 months. They examined the liver by ultrasonography every 3 months after randomization. The primary endpoint of this study was the appearance of a histologically confirmed recurrence or new hepatoma.
Treatment with polyprenoic acid significantly reduced the incidence of recurrent or new hepatomas. After a median follow-up period of 38 months, 12 (27%) in the polyprenoic acid group had recurrence or new hepatomas compared with 22 (49%) in the control group (P = 0.04). The most striking difference was in the groups that had second primary tumors: 7 in the polyprenoic acid group vs 20 in the placebo group (P = 0.04) (Fig. 8) . Thus, oral polyprenoic acid prevents the second primary hepatomas after surgical resection of the original tumor or the percutaneous injection of ethanol.
In this section, chemoprevention of HCC was reviewed only with respect to the main randomized clinical trials that have been conducted so far.
BREAST CANCER
It was Beatson (83) who revealed the relationship between the ovary and breast cancers for the first time in 1896, based on the observation that ovariectomy from premenopausal women with metastatic breast cancer could cause disease regression and extend survival in selected cases. Even at the time when the endocrine role of the ovaries and their production of steroidal hormones were totally unknown, a close relationship was thus established between an ovarian factor and the growth of breast cancer.
Research conducted in the 1920s led to the discovery of estrogens produced by the ovaries and circulating in the blood. Soon it was established that the breast is one of the target tissues under their endocrine control. In 1936, Lacassagne (84) for the first time suggested the concept of chemoprevention of breast cancer: its prevention by developing a therapeutic antagonist of estrogen action.
To assess the estrogen action, a model using ovariectomized mice was developed by Allen and Doisy (85) . Parallel to this, research into the synthesis of non-steroidal antiestrogenic drugs was conducted based on triphenylethylene-structured compounds, resulting in the development of tamoxifen.
Tamoxifen prevented DMBA-induced or MNU-induced beast cancers in rats (86) (87) (88) and also inhibited spontaneous mammary carcinogenesis in high-incidence strains of mice (89). 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) . Figure 8 . Kaplan-Meier estimates of the proportion of patients without second primary hepatomas with and without polyprenoic acid (82) .
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The first clinical observation of tamoxifen's efficacy as a chemopreventive agent was a report by Cuzick and Baum (90), who described a decreased incidence of contralateral breast cancer in women taking this drug. This observation has been confirmed by other randomized clinical trials (91) . Tamoxifen has since been extensively tested in clinical trials of adjuvant therapy for breast cancer for 20 years.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 study (92) started in 1992 with a primary endpoint of determining whether or not the use of tamoxifen reduced the incidence of invasive breast cancer in high-risk women. A randomized clinical trial was carried out on 13 388 women at increased risk for breast cancer for: (i) 60 years of age or older, (ii) 35-59 years of age with a 5-year predicted risk for breast cancer of at least 1.66%, (iii) a history of lobular carcinoma in situ. They were randomly assigned to receive 20 mg/day tamoxifen (n = 6681) or placebo (n = 6707) for 5 years. A multivariate logistic regression model by Gail et al. (93) using combinations of risk factors was used to estimate the risk of occurrence of breast cancer. Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P < 0.00001), with cumulative incidence through 69 months of follow-up of 22.0 vs 43.4 per 1000 women in the tamoxifen and placebo groups, respectively. This was a definitive result indicating that tamoxifen is effective as a chemopreventive agent for those who are at high risk of breast cancer. However, it was also found that participants who received tamoxifen had a 2.53 times greater risk of developing an invasive endometrial cancer than did women who received placebo. The increased risk was predominantly in women 50 years of age or older. Invasive cancers at sites other than the breast and endometrium were equally distributed. Of particular importance were the observations that no liver cancers occurred in either group and there was no increase in the incidence of colon, rectal, ovarian or other genitourinary tumors.
The number of participants who had a myocardial infarction in the tamoxifen and placebo groups was 31 and 28, respectively. Fractures of the hip, radius and spine were also evaluated. A total of 955 women experienced bone fractures, 472 and 483 in the tamoxifen and placebo groups, respectively. Pulmonary emboli were observed in almost three times as many women in the tamoxifen group than in the placebo group (18 vs 6; RR = 3.01).
As a second-generation selective estrogen receptor modulator (SERM), raloxifene (Fig. 9) was developed, which has the potential for preventing breast cancer while producing the beneficial effects of estrogen in postmenopausal women such as decreasing the risk of osteoporosis.
Two clinical trials to test the efficacy of raloxifene for prevention of osteoporosis identified that it could reduce the incidence of breast cancer as a beneficial side-effect of the prevention of osteoporosis. The multiple outcomes of raloxifene evaluation (MORE) randomized 7704 postmenopausal women of mean age 66.5 years who had osteoporosis but had no history of breast or endometrial cancer to placebo or 60 or 120 mg raloxifene daily. Results at 4 years showed a 72% reduction in the risk of breast cancer (94) .
The longer-term effect of raloxifene 60 mg/day on reducing the incidence of breast cancer in postmenopausal women will be evaluated in the Continuing Outcomes Relevant to Evista (CORE) trial. This study will follow the incidence of breast cancer in a subset of the MORE cohort for an additional 4 years.
The results in these trials provide the framework for the next breast cancer prevention trial, namely the P. 2 Study of Tamoxifen and Raloxifene (STAR) trial. This trial is comparing the current standard of care with the test drug raloxifene in postmenopausal women with a high risk of developing breast cancer (95).
HEAD AND NECK CANCER
Head and neck cancers are defined as cancers arising in the tongue, oral cavity, pharynx, larynx, tonsils, thyroid and upper Several randomized chemoprevention trials involving retinoids and/or b-carotene are ongoing or have been completed in the head and neck area which were summarized by Khuri et al. (96) . Retinoids including retinol, retinyl palmitate, all-transretinoic acid (ATRA), 13-cis-retinoic acid (13-CRA), etretinate and 4-N-(hydroxyphenyl)retinamide (4HPR) are the most frequently and extensively studied agents for head and neck cancer. Chemoprevention trials using retinoids aim at head and neck cancer to reverse oral preneoplastic lesions or to prevent the development of second primary tumors.
Oral preneoplastic lesions such as leukoplakia and erythroplakia have a risk of developing oral cancer from 5% to 30-40%. As is summarized in Table 5 , two placebo-controlled trials have been conducted for b-carotene in oral leukoplakia. Stich et al. (97) reported that combined b-carotene plus retinol, b-carotene alone and placebo exhibited complete response rates of 27.5, 14.8 and 3.0%, respectively. In 1986, Hong et al. (98) reported the results of a prospective, randomized, doubleblind clinical trial of high-dose 13-CRA (1-2 mg/kg/day) in oral leukoplakia. Clinical responses were observed in 16 (67%) of the 24 patients in the 13-CRA group and in two (10%) of 20 patients in the placebo group (P = 0.002). Reversal of dysplasia was also higher in the 13-CRA group (54 vs 10%, P = 0.01). Substantial toxicity of 13-CRA and a high rate of relapse of >50% within 2-3 months of discontinuing therapy were serious clinical problems.
Concerning the toxicity and relapse problems, Lippman et al. (99) studied the effect of low-dose 13-CRA. Low-dose (0.5 mg/kg/day) 13-CRA maintenance was well tolerated together with a 55% response rate by high-dose (1.5 mg/kg/day) induction therapy. Table 5 .
Concerning the prevention of second primary tumors following treatment of early head and neck squamous cell carcinomas, Hong et al. (103) conducted a randomized, double-blind, placebo-controlled trial of high-dose 13-CRA as adjuvant therapy after curative surgery and/or radiation therapy.
A total of 103 patients were randomly assigned to receive either high-dose 13-CRA (50-100 mg/m 2 /day) or placebo for 12 months. By 32 months after intervention, the incidence of second primary tumors was 4% in 13-CRA-treated patients and 24% in the placebo group (P = 0.005). However, the toxicity of high-dose 13-CRA was severe and one-third of the retinoid-treated patients required dose reduction or termination of therapy.
Pastorino et al. (104) used retinyl palmitate 300 000 IU/day for 12 months to prevent second primary tumors in patients having a prior history of primary stage I non-small cell lung cancer. A reduction in the incidence of second primary tumors and a prolongation of time to development of tobacco-related second primary tumors were observed in the retinoid arm. Only 13 second primary tumors were observed in patients in the retinyl palmitate arm versus 25 in control patients. (Table 6 ).
To resolve the conflicting results of the two previous second primary tumors trial, the University of Texas MD Anderson Cancer Center launched in 1992 the largest head and neck cancer chemoprevention trial with a plan to recruit 1302 patients with stage I or II head and neck squamous cell carcinomas treated with surgery or radiation therapy. Patients were randomly assigned to receive either 30 mg/day of 13-CRA for 3 years or a placebo. Regarding toxicity of 13-CRA, a lower dose than in the trial of Hong et al. (103) mentioned above was relatively well tolerated.
Head and neck cancers are a good target for chemoprevention regarding inhibition of second primary tumors using vitamin A analogues and retinoids. Less toxic agents are expected to be developed in the future that can be used for a longer time. There are two enzymes, COX-1 and COX-2, as the cyclooxygenases (prostaglandin H synthase) which catalyze both oxidative and reductive reactions in the prostaglandin synthesis pathway. COX-1, which is a constitutive enzyme, is detectable in the human colon of all normal subjects, whereas for COX-2, which is an inducible enzyme, its gene expression is increased in human colon carcinomas. It is postulated that increased COX-2 expression plays a major role in over-expression of prostaglandins in malignant tissues.
To determine whether the regular use of aspirin, which is an inhibitor of COX-1 and COX-2, decreases the risk of colorectal cancer, a prospective cohort study (107) was conducted with 47 900 male health professionals, 40-75 years of age, throughout the USA who responded to a mailed questionnaire in 1986. The questionnaires aimed to assess the use of aspirin and other variables including occurrence of cancer in 1986, 1988 and 1990; 251 new patients were diagnosed with colorectal cancer during the study period. Regular users of aspirin (twice or more per week) in 1986 had a lower risk of total colorectal cancer (RR = 0.68) and advanced (metastatic and fatal) colorectal cancer (RR = 0.51). These results support the contention that regular use of aspirin is associated with a decreased risk for colorectal cancer. Multiple population-based case-controlled studies have been conducted and aspirin repeatedly exhibited a 50% reduction in risk of occurrence of colorectal cancer (108) .
Related to prostaglandin synthesis, many human studies using various NSAIDs have been conducted. Patients with familial adenomatous polyposis, who are at extremely highrisk for colon cancer, are a good target for chemoprevention. Three of these studies were small, randomized clinical trials using sulindac as a chemopreventive agent. Combining these trials, 45 FAP patients were treated in these studies and administration of sulindac resulted in a statistically significant decrease in the number of polyps (109, 110) . A COX-2 inhibitor, celecoxib, was tested at 100 mg twice daily and 400 mg twice daily for 6 months (111). Treatment with 100 mg resulted in a 12% decrease in the number of polyps. Celecoxib at 400 mg reduced the number of polyps by 28% from the baseline, which was statistically significant. The major issue regarding the beneficial effects of NSAIDs and COX-2 inhibitors on polyp formation is that these effects are transient and disappear soon after drug withdrawal. Table 7 shows the agents under study for chemoprevention of colorectal tumors including non-selective NSAIDs and selective NSAIDs (COX-2 inhibitors).
Epidemiological data regarding the association between calcium ingestion and colorectal cancer risk are not yet solid. A number of case-control and cohort studies have suggested that increased intake of calcium and vitamin D may have some protective effect. However, other studies have not clearly supported this association (112) . Calcium may bind with bile and fatty acids in the intestinal lumen, decreasing exposure of the large bowel epithelium to these substances.
Curcumin has strong antiproliferative effects established on human colon cancer cell models (113) . Preclinical and early clinical pharmacological data suggest that curcumin is poorly absorbed through the gastrointestinal tract, making it an attractive candidate for chemoprevention of gastrointestinal cancer (114) .
Hormone-replacement therapy in postmenopausal women and its effects in colorectal cancer have been evaluated in many studies. Postmenopausal use of hormones was associated with a significant decrease in colorectal cancer mortality in the Cancer Prevention Study II with an overall RR of 0.71 (115) .
a-Difluoromethylornithine (DFMO) is the main class of inhibitors of ornithine decarboxylase (ODC) activity. A shortterm phase IIa trial by Meyskens et al. (116) demonstrated that DFMO at 0.10 g/m 2 /day was able to inhibit polyamine production in rectal mucosa after 1 month. They concluded that a dose of 0.50 g/m 2 /day of DFMO was safe and effective and they therefore recommended this dose level of administration for use in combination phase IIb or single-agent phase III chemoprevention trials (117).
LUNG CANCER
Lung cancer is the number one cause of death due to cancer in the USA, exceeding breast, prostate and colon cancer deaths combined. Known risk factors for the development of lung cancer include smoking cigarettes, asbestos exposure and radon exposure. Five RCTs of chemoprevention have been reported (118) for subjects with one or more of these risk factors.
The ATBC trial (119) examined the effect of a-tocopherol and b-carotene on the incidence of lung cancer in 29 133 Finnish male smokers using a 2 ´ 2 factorial design. The selection of a-tocopherol and b-carotene was based on epidemiological studies linking a vegetable-rich diet with a decrease in the risk of lung cancer.
Subjects recruited between 1985 and 1993 took supplements of a-tocopherol 50 mg/day and b-carotene 20 mg/day for 5-8 years (mean 6.1 years). No effect of a-tocopherol on lung cancer incidence was observed. However, the RR of lung cancer incidence in the b-carotene arms was 1.18 (95% CI, 1.03 to 1.36). That means b-carotene increased the risk of lung cancer 18%.
The CARET study (120) (The Carotene and Retinol Efficacy Trial) was a large two-arm study that was designed to compare the effects of a combination of b-carotene and retinol with those of placebo on lung cancer incidence in subjects who were at high risk for the development of lung cancer. This study was based on the epidemiological observation indicating decreased RR of lung cancer in subjects showing high dietary intake and serum levels of b-carotene and vitamin A. A pilot study (121) of 1029 high-risk subjects demonstrated the safety and tolerability of b-carotene 50 mg/day, retinol 25 000 IU/day and the combination of the two. The CARET study enrolled a total of 18 314 subjects, including current and former smokers of both (122) . The Physicians' Health Study (123) was a randomized, double-blind, placebo-controlled trial of aspirin, 325 mg every other day and b-carotene, 50 mg every other day, conducted using a 2 ´ 2 factorial design among 22 071 male physicians in the USA. The study began in 1982 and the aspirin arms were terminated in 1988 when a significant reduction in first myocardial infarction incidence was noted. An analysis of the cancer incidence in patients in the b-carotene arms at the end of the study in 1995 showed no significant difference in the incidence of lung cancer.
The Women's Health Study (124) recruited nearly 40 000 women for RCT who were at least 45 years of age in a 2 ´ 2 2 factorial design to assess the effect of b-carotene, aspirin and vitamin E on incidences of cancer and cardiovascular disease. Following the publication of other studies, the b-carotene arm was closed. Supplementation of b-carotene was continued for 2.1 years and additionally followed up for 2.0 years (median total follow-up, 4.1 years). There was no difference in cancer incidence or death regarding b-carotene supplementation. Thirty cases of lung cancer were observed in the b-carotene arms and 21 cases in the placebo arms (RR 1.42; 95% CI, 0.88 to 2.49), a result that is not statistically significant.
An Australian study (125) of 1024 asbestos workers randomly assigned subjects in equal proportions to either b-carotene 30 mg/day or retinol 25 000 IU/day from 1990 to 1995; 21% of subjects were current smokers and 52% were former smokers. After a median intervention and follow-up period of 4.5 years, no difference in lung cancer incidence was found (RR 0.66; 95% CI, 0.19 to 2.32). The incidence of malignant mesothelioma was statistically significantly lower in the retinol group than the b-carotene group (RR 0.24; 95% CI, 0.07 to 0.86).
From the disappointing experiences of the ATBC Study and CARET, in the next generation of chemoprevention trials, systematic application of DNA microarray and proteomics methods will be considered to investigate influences of genetic polymorphisms, validated surrogate endpoints, epigenetic relationships and so forth. We have at least to bear in mind the possibility of hazardous effects of chemopreventive agents.
IV. DISCUSSION
There are large amounts of papers and experimental results regarding the effectiveness of specific agents on chemoprevention. However, the number of agents proved to be effective by clinical trials are very few. We can point out several background factors for this discrepancy. (i) Clinical trials conducted serially as phase I, II and III studies need enormous amounts of money. For example, a prostate cancer prevention trial using finasteride (56) required almost 8 billion yen. As mentioned earlier regarding the EORTC experience (62), the average cost per patient involved in a phase III study was between US$1000 and 2000, indicating that for a sample-size of 30 000 men, US$20-40 million are needed. (ii) Pharmaceutical companies are not interested in developing new agents for chemoprevention because of the high R & D costs and low profit after clinical trials. (iii) The target population for chemoprevention is healthy volunteers or a high-risk group of people for specific cancers. This is a serious difference from clinical trials with new chemotherapeutic agents, where patients are actually suffering from cancer and these new agents are applied as a step of treatment. Consequently, it may not be easy to conduct a large-scale study, particularly for a country such as Japan. The USA is a rich, powerful country which can afford large grants for large-scale clinical trials for chemoprevention. If we consider a clinical trial in Japan, I think, it is necessary to concentrate on extremely high-risk groups of people. Using small numbers of participants, well-designed clinical trials can prove the effectiveness of some agents, as was described for hepatocellular carcinoma in this review. In this respect, we have to focus our attention on the cancers common in Japan such as gastric cancer and liver cancer. The USA and Europe will concentrate on large-scale chemoprevention studies on prostate cancer, breast cancer, colorectal cancer and so forth. Such types of allocation of targets may be necessary.
In the near future, we will be able to use genetic information on individuals regarding their cancer susceptibility on the condition that their privacy is strictly protected. In such a setting, a chemoprevention study for a high-risk group may become more sharply focused.
For further development of chemoprevention studies in Japan, the amounts of grants from the government should be expanded, infrastructures such as data management centers should be more strengthened and the concept of preventive coverage should be introduced to the health insurance system.
In planning future clinical trials, we have to bear in mind the lessons we have learned already, such as the unexpected results of the b-carotene studies (120, 121) . We should also be reminded that it is necessary to evaluate multi-organ systems for the effectiveness of any agent because such an agent may exhibit inhibition of cancer in one organ but may promote cancer in others. We need more basic research on chemoprevention from the viewpoint of biological mechanisms.
